Phase 4 N=40 Effects of Modafinil in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 New Medication Treatment for Stimulant Dependence
Cocaine Dependence
Primary: Cocaine Use by Self-report — 67; 67 Percent of cocaine-free (abstinent)days — p=0.972
Phase 2 N=81 A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05
Phase 1 N=31 Staccato Alprazolam Abuse Liability
Abuse Liability of Staccato Alprazolam
Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale
Phase 2 N=73 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
Phase 3 N=471 Stimulant Abuser Groups to Engage in 12-Step
Drug Abuse
Primary: Days of Stimulant Use — 2.35; 2.13 days of stimulant use — p=<0.05
Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Phase 2 N=20 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity · Cocaine-Related Disorders
Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants
Phase 3 N=126 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
Adult Attention Deficit Hyperactivity Disorder · Cocaine Dependence
Primary: Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use — 7; 18; 30 percentage of participants
Phase 2 N=22 Doxazosin for Psychostimulant Dependence
Methamphetamine or Cocaine Dependence
Primary: Change in Psychostimulant-positive Urines Over Time — .6; .41; .79; .25 proportion of psychostimulant-pos urines — p=0.05
Phase 2 N=81 Medications for Stopping Cocaine Dependence and Preventing Relapse
Cocaine Abuse · Cocaine-Related Disorders
Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines
Phase 4 N=33 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Phase 2 N=50 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
Substance Abuse
Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples
Phase 1 N=12 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=8 Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Phase 2 N=43 Treatment of Cocaine Dependence With Lisdexamfetamine
Cocaine Dependence
Primary: Cocaine-positive Urine Results — 86.5; 92.4 percentage of BE urine tests
N/A N=40 Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Phase 3 N=127 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants
Phase 2 N=71 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
Phase 2 N=13 Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Phase 2 N=13 Modafinil for Smoked Cocaine Self-Administration
Cocaine Dependence
Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased
Phase 2 N=17 Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
Cocaine Dependence
Primary: Number of Participants Maintained on the Maximum Lisdexamfetamine Daily Dose. — 12 Participants
N/A N=60 A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
Amphetamine Abuse · Amphetamine Dependence · Bipolar Disorder
Primary: Depression Symptoms — 26.2; 33.1 scores on a scale — p=0.05
Phase 2 N=20 Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction
Cocaine Addiction · Cocaine-related Disorder · Executive Dysfunction
Primary: Abstinence — 71.4; 16.6 percentage of participants